cenpm Antibody

What is CENPM and why is it significant in cancer research?

CENPM (Centromere Protein M) is a protein involved in chromosome segregation during cell division. Its significance in cancer research has grown substantially as recent studies have identified it as a potential oncogene in several cancer types. CENPM has been found to promote carcinogenesis, particularly in breast cancer, by altering cellular pathways related to proliferation and immune infiltration . Research also indicates its involvement in glycolytic reprogramming in glioblastoma (GBM), suggesting a role in cancer metabolism . To study CENPM's function, researchers typically utilize techniques such as RT-qPCR for mRNA expression analysis and Western blotting for protein detection, with GAPDH commonly serving as a reference gene for normalization .

What applications are CENPM antibodies most commonly used for?

CENPM antibodies are primarily utilized in several key molecular biology techniques. Western Blotting (WB) is the most common application, allowing researchers to detect and quantify CENPM protein levels in cell and tissue lysates. Additional applications include ELISA for quantitative protein detection, Immunohistochemistry (IHC) for visualizing CENPM localization in tissue sections, and Immunofluorescence (IF) for subcellular localization studies . When selecting an antibody, researchers should consider the specific region of CENPM being targeted (internal region, C-terminal, etc.) as this affects specificity and application suitability. For example, antibodies targeting the internal region of CENPM have demonstrated efficacy in detecting endogenous levels of total CENPM protein across various applications .

How do I choose the appropriate CENPM antibody for my research?

Selecting the appropriate CENPM antibody requires consideration of several factors based on your experimental design:

• Target specificity: Determine which region of CENPM you wish to target. Commercially available antibodies target different epitopes including internal regions, C-terminal domains, and middle regions. Each may have different detection sensitivities .

• Host species: Consider the host species (rabbit, mouse, rat) in relation to your experimental design, particularly if performing co-staining with other antibodies .

• Clonality: Polyclonal antibodies offer broader epitope recognition but potentially lower specificity, while monoclonal antibodies provide higher specificity to a single epitope .

• Species reactivity: Verify the antibody's reactivity with your experimental model organism. Many CENPM antibodies react with human samples, while cross-reactivity with mouse, pig, bovine, and other species varies by product .

• Validated applications: Ensure the antibody has been validated for your specific application (WB, ELISA, IHC, IF, IP) through published literature or manufacturer testing .

Most importantly, review published literature using your antibody of interest to assess its performance in contexts similar to your research question.

What are the best practices for CENPM antibody validation?

Thorough validation of CENPM antibodies is essential for generating reliable and reproducible results. A comprehensive validation approach should include:

• Positive and negative controls: Use cell lines or tissues known to express CENPM (positive control) and those with low or no expression (negative control). For breast cancer research, comparing normal breast tissue with tumor samples provides valuable control materials .

• Knockdown/knockout verification: Employ shRNA-mediated knockdown or CRISPR/Cas9 knockout of CENPM to confirm antibody specificity. The decreased signal in Western blot or immunostaining after CENPM knockdown strongly supports antibody specificity .

• Multiple detection methods: Validate antibody performance across different techniques (Western blot, IHC, IF) to ensure consistent results across platforms.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to confirm binding specificity.

• Molecular weight verification: Confirm that the detected band in Western blot corresponds to the expected molecular weight of CENPM (approximately 31 kDa).

• Cross-validation with different antibodies: Compare results using antibodies targeting different epitopes of CENPM to ensure consistency in detection patterns.

• Correlation with mRNA expression: Correlate protein detection with mRNA levels measured by RT-qPCR to verify that protein expression patterns match transcriptional patterns .

How can I optimize Western blot protocols for CENPM detection?

Optimizing Western blot protocols for CENPM detection requires attention to several critical parameters:

• Sample preparation: For optimal CENPM detection, use a lysis buffer that preserves protein integrity while effectively extracting nuclear proteins. RIPA buffer supplemented with protease inhibitors and phosphatase inhibitors is generally effective for CENPM extraction. For nuclear proteins like CENPM, consider including DNase treatment to reduce sample viscosity .

• Protein loading optimization: CENPM is often expressed at moderate levels; load 20-30 μg of total protein per lane for cell lines and 40-50 μg for tissue samples. Gradient gels (4-15%) may improve resolution.

• Transfer conditions: Use PVDF membranes for better protein retention and signal-to-noise ratio compared to nitrocellulose when detecting CENPM . Optimize transfer time (typically 60-90 minutes at 100V) or consider semi-dry transfer systems.

• Blocking optimization: 5% non-fat dry milk in TBST typically provides adequate blocking, but for phospho-specific CENPM detection, 5% BSA may yield better results.

• Antibody dilution and incubation: Optimal primary antibody dilutions for CENPM detection typically range from 1:1000 to 1:5000, with overnight incubation at 4°C providing the best signal-to-noise ratio . Secondary antibody at 1:2000-1:5000 for 1-2 hours at room temperature is generally sufficient.

• Signal development: For subtle expression differences, chemiluminescence detection with longer exposure times may be necessary. For quantitative comparisons, consider fluorescent secondary antibodies and digital imaging systems.

• Stripping and reprobing: When comparing CENPM with other proteins of similar molecular weight, prepare parallel blots rather than stripping and reprobing, which can reduce signal intensity and compromise quantitative accuracy.

Using β-actin (42 kDa) as a loading control provides good separation from CENPM bands on standard gels .

What methodological approaches are most effective for studying CENPM's role in cancer progression?

To effectively investigate CENPM's role in cancer progression, researchers should implement a multi-faceted approach:

• Expression analysis in patient samples:

  • Analyze TCGA and GEO databases to examine CENPM expression across cancer types and correlate with clinical outcomes

  • Perform immunohistochemistry on tissue microarrays to validate expression patterns in independent patient cohorts

  • Correlate expression with clinicopathological features including tumor stage, grade, and patient survival

• Functional studies using gene modulation:

  • Utilize shRNA-mediated knockdown to silence CENPM expression (multiple shRNA constructs are recommended to control for off-target effects)

  • Employ CRISPR/Cas9-based knockout for complete gene inactivation

  • Use overexpression systems (pcDNA3.1 vectors) to assess effects of increased CENPM levels

  • Validate gene modulation efficiency via both RT-qPCR and Western blot

• Phenotypic assays:

  • Proliferation assays (CCK8, colony formation) to assess growth effects

  • Migration and invasion assays (scratch, transwell) to evaluate metastatic potential

  • Metabolic assays (glycolysis, oxygen consumption) to investigate metabolic reprogramming

  • EMT marker analysis (E-cadherin, N-cadherin, Snail, Twist) via Western blot

• Mechanistic investigations:

  • Pathway analysis using enrichment tools (clusterProfiler)

  • Protein-protein interaction studies (co-immunoprecipitation, proximity ligation assay)

  • Chromatin immunoprecipitation to identify transcriptional targets

• In vivo validation:

  • Xenograft models using CENPM-modulated cell lines

  • Patient-derived xenografts to maintain tumor heterogeneity

  • Orthotopic models for tissue-specific microenvironment effects

The integration of these approaches provides comprehensive insight into CENPM's cancer-promoting mechanisms, from molecular interactions to clinical significance.

How can I investigate the relationship between CENPM expression and immune infiltration?

Investigating the relationship between CENPM expression and immune infiltration requires a multi-dimensional approach combining computational analysis and experimental validation:

• Computational immune profiling:

  • Use GSVA (Gene Set Variation Analysis) package to examine immune cell infiltration patterns in relation to CENPM expression levels

  • Apply single-sample Gene Set Enrichment Analysis (ssGSEA) to categorize samples based on CENPM expression and compare immune infiltration levels

  • Utilize TIDE (Tumor Immune Dysfunction and Exclusion) algorithm to predict response to immune checkpoint inhibitors in relation to CENPM expression

• Flow cytometry analysis:

  • Analyze tumor-infiltrating lymphocytes (TILs) isolated from mouse models with modulated CENPM expression

  • Quantify CD8+ T cells, Tregs, Th2 cells, and mast cells, which have shown correlation with CENPM expression

  • Use multi-parameter flow cytometry to simultaneously assess multiple immune cell populations

• Cytokine profiling:

  • Conduct ELISA assays to measure cytokine secretion in the tumor microenvironment, particularly from macrophages

  • Assess cytokine profiles in supernatants from cell culture systems with CENPM knockdown versus control

  • Use cytokine arrays to identify broader patterns of immune signaling affected by CENPM

• Co-culture experiments:

  • Establish co-culture systems between cancer cells with modulated CENPM expression and immune cells (T cells, macrophages)

  • Assess immune cell activation, cytokine production, and cytotoxic activity

  • Use transwell systems to distinguish between contact-dependent and secreted factor-mediated effects

• Immunohistochemistry validation:

  • Perform multiplexed IHC on tumor tissues to correlate CENPM expression with immune cell infiltration in situ

  • Quantify spatial relationships between CENPM-expressing cells and immune populations

The correlation table below summarizes findings from breast cancer research regarding CENPM expression and immune cell infiltration:

This multi-faceted approach provides comprehensive insight into how CENPM influences the tumor immune microenvironment, potentially informing immunotherapy strategies .

What approaches should I use to study CENPM's influence on metabolic reprogramming in cancer cells?

Investigating CENPM's role in cancer metabolic reprogramming requires specialized experimental approaches focusing on glycolytic pathways and energy metabolism:

• Glycolytic flux measurement:

  • Employ extracellular acidification rate (ECAR) analysis using Seahorse XF technology to quantify glycolytic capacity in real-time

  • Measure lactate production in cell culture supernatants as an indicator of glycolytic activity

  • Assess glucose uptake using fluorescent glucose analogs (2-NBDG) or radiolabeled glucose

• Metabolic enzyme expression and activity:

  • Quantify key glycolytic enzymes (HK2, LDHA) via Western blot analysis following CENPM modulation

  • Measure enzymatic activities of hexokinase, phosphofructokinase, and lactate dehydrogenase using spectrophotometric assays

  • Investigate protein-protein interactions between CENPM and metabolic enzymes through co-immunoprecipitation

• Metabolomics analysis:

  • Conduct targeted metabolomics focusing on glycolytic intermediates and TCA cycle metabolites

  • Analyze the metabolic profile shift after CENPM knockdown or overexpression

  • Trace metabolic flux using 13C-labeled glucose or glutamine followed by mass spectrometry

• Mitochondrial function assessment:

  • Measure oxygen consumption rate (OCR) to determine if CENPM affects oxidative phosphorylation

  • Assess mitochondrial membrane potential using fluorescent probes (TMRE, JC-1)

  • Quantify ATP production via luminescence-based assays under different metabolic conditions

• In vivo metabolism studies:

  • Utilize PET imaging with 18F-FDG to monitor glucose uptake in xenograft models with modified CENPM expression

  • Analyze tumor sections for metabolic enzyme expression via IHC

  • Perform ex vivo metabolomics on excised tumors to correlate CENPM expression with metabolic profiles

• Rescue experiments:

  • Determine if metabolic inhibitors (2-DG, oxamate) can abrogate effects of CENPM overexpression

  • Test if metabolic substrate supplementation can rescue phenotypes caused by CENPM knockdown

For Western blot analysis of metabolic enzymes after CENPM modulation, researchers should examine:

These approaches collectively provide a comprehensive understanding of how CENPM contributes to metabolic reprogramming in cancer cells, potentially revealing new therapeutic vulnerabilities .

How do I troubleshoot non-specific binding or background issues with CENPM antibodies?

Non-specific binding and high background are common challenges when working with CENPM antibodies. Here's a systematic approach to troubleshooting these issues:

• Antibody validation concerns:

  • Verify antibody specificity using positive and negative controls (cell lines with known CENPM expression levels)

  • Test antibody on lysates from CENPM knockdown cells to confirm the disappearance of the specific band

  • Consider testing alternative antibodies targeting different CENPM epitopes

• Western blot background issues:

  • Increase blocking stringency: Extend blocking time to 2 hours or overnight at 4°C

  • Optimize blocking agent: Test 5% BSA versus 5% non-fat dry milk in TBST

  • Increase washing duration and frequency: Perform 5 washes of 5-10 minutes each with TBST

  • Reduce primary antibody concentration: Test serial dilutions (1:500, 1:1000, 1:2000, 1:5000)

  • Add 0.1-0.5% Tween-20 to antibody dilution buffer to reduce non-specific binding

  • Use highly purified antibodies that underwent affinity chromatography purification

• Immunohistochemistry/Immunofluorescence background:

  • Implement antigen retrieval optimization: Test different pH buffers and retrieval times

  • Block endogenous peroxidase activity: Use 3% hydrogen peroxide before antibody incubation

  • Add species-specific serum (10%) to blocking buffer

  • Include 0.1-0.3% Triton X-100 in blocking buffer to improve antibody penetration

  • Use specialized blocking reagents to reduce tissue-specific background

• Sample preparation considerations:

  • Ensure complete protease inhibition during lysate preparation

  • Remove cellular debris thoroughly by centrifugation

  • For tissue samples, optimize fixation protocols to preserve epitope integrity

  • Consider background caused by post-translational modifications of CENPM

• Detection system optimization:

  • Use highly cross-adsorbed secondary antibodies to minimize cross-reactivity

  • For fluorescent detection, include an extra blocking step with normal serum from secondary antibody host species

  • Reduce exposure time during image capture while enhancing signal with digital processing

By systematically addressing these variables, researchers can significantly improve signal-to-noise ratio when detecting CENPM in various experimental contexts.

What are the most common pitfalls in comparing CENPM expression levels across different cancer types or tissues?

Comparing CENPM expression across different cancer types or tissues presents several methodological challenges that must be carefully addressed to generate reliable data:

• Tissue/sample heterogeneity:

  • Cancer samples have varying cellular compositions, with different proportions of tumor cells, stromal cells, and immune infiltrates

  • Solution: Use microdissection techniques to isolate tumor cells, or employ computational deconvolution methods to account for cellular heterogeneity in bulk RNA-seq data

  • Normalize expression data to tumor purity estimates derived from histopathological assessment

• Technical variations in detection methods:

  • Different antibody clones may have varying affinities and epitope specificities

  • Solution: Standardize antibody selection, concentration, and detection protocols across all samples

  • Include universal control samples across multiple experiments to enable inter-experimental normalization

  • Use the same detection platform (e.g., same imaging system, scanner settings) for all samples

• Reference gene/normalization challenges:

  • Traditional housekeeping genes may vary in expression across tissue types or disease states

  • Solution: Validate stability of reference genes (e.g., GAPDH, β-actin) in your specific tissue types

  • Consider using multiple reference genes and geometric averaging of normalization factors

  • For RNA-seq data, use specialized normalization methods like TMM (Trimmed Mean of M-values) or quantile normalization

• Biological context interpretation:

  • CENPM may have tissue-specific functions or different baseline expression levels

  • Solution: Always include matched normal tissues as controls for each cancer type

  • Consider relative fold changes rather than absolute expression values

  • Validate findings using orthogonal methods (e.g., RT-qPCR, Western blot, and IHC)

• Database-specific biases:

  • Public databases like TCGA may have batch effects or platform-specific biases

  • Solution: Apply batch correction algorithms before comparative analyses

  • Validate findings across multiple independent datasets (TCGA, GEO, institutional cohorts)

  • Consider meta-analysis approaches to integrate evidence across studies

• Statistical considerations:

  • Different sample sizes across cancer types affect statistical power

  • Solution: Use appropriate statistical tests that account for unequal variances and sample sizes

  • Apply multiple testing corrections when comparing across numerous cancer types

  • Report confidence intervals alongside p-values to indicate precision of estimates

By addressing these challenges methodically, researchers can generate more reliable comparative data on CENPM expression across diverse cancer contexts.

How can I resolve contradictory data regarding CENPM function in different experimental systems?

Resolving contradictory data about CENPM function across different experimental systems requires a systematic approach to understand context-specific effects and methodological variations:

• Cell line-specific effects analysis:

  • Different cell lines may represent distinct molecular subtypes with unique dependencies

  • Solution: Characterize baseline CENPM expression and molecular profiles across cell line panels

  • Test CENPM modulation in multiple cell lines representing different cancer subtypes

  • Correlate functional outcomes with molecular features (mutation status, gene expression profiles)

• Knockdown/overexpression methodology differences:

  • Varying levels of CENPM knockdown or overexpression may produce different phenotypes

  • Solution: Quantify knockdown/overexpression efficiency precisely using RT-qPCR and Western blot

  • Use multiple shRNA sequences targeting different regions of CENPM to control for off-target effects

  • Create dose-response curves by titrating expression vectors or shRNA constructs

  • Implement rescue experiments to confirm specificity of observed phenotypes

• Experimental timing considerations:

  • Acute versus chronic CENPM modulation may yield different results

  • Solution: Establish time-course experiments capturing immediate, intermediate, and long-term effects

  • Use inducible systems (e.g., Tet-On/Off) to control timing of CENPM modulation

  • Monitor phenotypic changes longitudinally rather than at single endpoints

• Microenvironmental context:

  • In vitro versus in vivo conditions may produce different outcomes

  • Solution: Compare 2D culture with 3D organoids and in vivo models

  • Assess CENPM function under various stress conditions (hypoxia, nutrient deprivation)

  • Consider co-culture experiments to evaluate cell-cell interaction effects

• Endpoint measurement standardization:

  • Different assays measuring the same biological process may yield different results

  • Solution: Use multiple complementary assays for key phenotypes (e.g., both CCK8 and colony formation for proliferation)

  • Standardize assay protocols, including cell densities, incubation times, and reagent concentrations

  • Include positive and negative controls in each assay to ensure assay performance

• Data integration approaches:

  • Develop network models integrating multiple datasets to identify context-dependent functions

  • Use meta-analysis approaches to determine effect sizes across studies

  • Implement Bayesian methods to quantify certainty/uncertainty about functional roles

  • Collaborate with computational biologists to develop predictive models of CENPM function

By systematically addressing these factors, researchers can resolve contradictory findings and develop a more nuanced understanding of CENPM's context-dependent functions in cancer biology.

How can CENPM expression be leveraged as a biomarker for cancer immunotherapy response?

CENPM shows significant potential as a predictive biomarker for immunotherapy response based on its established connections to immune cell infiltration and checkpoint pathways:

• Current evidence supporting CENPM as an immunotherapy biomarker:

  • CENPM expression correlates with altered immune cell infiltration patterns, including decreased CD8+ T cells and increased regulatory T cells

  • High CENPM expression shows co-expression with multiple immune checkpoint genes

  • TIDE algorithm analysis indicates groups with high CENPM expression demonstrate greater immunotherapy response potential

• Clinical implementation strategies:

  • Develop standardized IHC protocols for CENPM detection in diagnostic pathology workflows

  • Establish optimal CENPM expression thresholds for predicting response through ROC curve analysis

  • Design multiplexed IHC panels combining CENPM with established markers (PD-L1, CD8, TILs)

  • Integrate CENPM status with other predictive biomarkers in composite scoring systems

• Validation approaches for clinical application:

  • Retrospective analysis of immunotherapy trial samples correlating pre-treatment CENPM levels with outcomes

  • Prospective collection of CENPM expression data in ongoing immunotherapy trials

  • Development of companion diagnostic assays with analytical and clinical validation

  • Multi-center validation studies to assess reproducibility across institutions

• Mechanistic studies to strengthen biomarker rationale:

  • Investigate how CENPM influences antigen presentation machinery

  • Explore CENPM's effect on tumor-intrinsic interferon signaling pathways

  • Assess impact on immune checkpoint expression and function

  • Determine if CENPM affects immune cell recruitment via chemokine modulation

• Treatment strategy optimization:

  • Investigate whether CENPM inhibition could sensitize tumors to immune checkpoint blockade

  • Test combination approaches targeting CENPM alongside immunotherapy

  • Explore whether monitoring CENPM expression during treatment could indicate developing resistance

  • Assess whether different immunotherapy modalities (anti-PD-1, anti-CTLA-4, cellular therapies) show varying associations with CENPM status

The correlation between CENPM expression and immune checkpoint genes supports its potential utility as a biomarker, with research indicating that patients with high CENPM expression may benefit more from immunotherapy approaches, particularly in breast cancer contexts .

What are the latest techniques for studying CENPM's protein interactions and post-translational modifications?

Investigating CENPM's protein interactions and post-translational modifications requires cutting-edge techniques that provide high-resolution insights into protein function and regulation:

• Advanced protein interaction mapping:

  • Proximity-dependent biotin identification (BioID) or TurboID for identifying proteins in close proximity to CENPM in living cells

  • APEX2 proximity labeling for temporally controlled interaction mapping

  • Quantitative SILAC-based immunoprecipitation to distinguish specific from non-specific interactions

  • Cross-linking mass spectrometry (XL-MS) to capture transient or weak interactions

  • Förster resonance energy transfer (FRET) microscopy for real-time interaction monitoring in live cells

• Post-translational modification (PTM) analysis:

  • Phosphoproteomics using titanium dioxide (TiO2) enrichment to identify CENPM phosphorylation sites

  • Ubiquitin remnant profiling using K-ε-GG antibodies to detect ubiquitination sites

  • SUMO-ID techniques to identify SUMOylation events on CENPM

  • Site-directed mutagenesis of predicted PTM sites followed by functional studies

  • Phos-tag SDS-PAGE to separate phosphorylated from non-phosphorylated CENPM species

• Structural biology approaches:

  • Cryo-electron microscopy (cryo-EM) for structural analysis of CENPM within larger complexes

  • Hydrogen-deuterium exchange mass spectrometry (HDX-MS) to map interaction interfaces

  • NMR spectroscopy for dynamic structural information in solution

  • Integrative structural modeling combining multiple data sources

• Temporal dynamics investigation:

  • FRAP (Fluorescence Recovery After Photobleaching) to measure CENPM mobility and binding kinetics

  • Optogenetic tools to induce or disrupt CENPM interactions with temporal precision

  • Single-molecule tracking to monitor CENPM dynamics in living cells

  • Cell cycle synchronization combined with time-course proteomics

• Functional validation of interactions and modifications:

  • CRISPR-based genetic screens to identify synthetic interactions with CENPM

  • Generation of PTM-specific antibodies for tracking modification status

  • Expression of PTM-mimetic or PTM-deficient CENPM mutants

  • Pharmacological inhibition of modifying enzymes to assess functional consequences

These advanced techniques provide comprehensive insights into CENPM's molecular interactions and regulatory mechanisms, potentially revealing new therapeutic targets within CENPM-associated pathways in cancer contexts.

What are the most promising therapeutic strategies targeting CENPM in cancer treatment?

Emerging research suggests several promising therapeutic strategies targeting CENPM that could be developed for cancer treatment:

• Direct CENPM inhibition approaches:

  • RNA interference therapeutics: Develop siRNA or shRNA delivery systems targeting CENPM mRNA

  • Antisense oligonucleotides: Design ASOs specifically targeting CENPM transcript

  • PROTAC (Proteolysis Targeting Chimera) technology: Create bifunctional molecules that target CENPM for ubiquitin-mediated degradation

  • Small molecule inhibitors: Identify compounds that disrupt CENPM's centromere localization or protein interactions

• Targeting CENPM transcriptional regulation:

  • E2F1 inhibitors: Since E2F1 drives CENPM expression, targeting this transcription factor could indirectly reduce CENPM levels

  • Epigenetic modulators: Explore histone deacetylase inhibitors or DNA methyltransferase inhibitors that may alter CENPM expression

  • Bromodomain inhibitors: Test their ability to disrupt transcriptional activation of CENPM

• Metabolic pathway intervention:

  • Glycolysis inhibitors: Target the metabolic pathways enhanced by CENPM expression

  • Hexokinase 2 (HK2) inhibitors: Block the glycolytic enzyme upregulated in CENPM-overexpressing tumors

  • LDHA inhibitors: Counteract the increased lactate production associated with CENPM-driven metabolic reprogramming

• Immunotherapy combination strategies:

  • Combine CENPM targeting with immune checkpoint inhibitors: This approach could counteract the immunosuppressive microenvironment associated with high CENPM expression

  • Develop CENPM-targeting CAR-T cells: Engineer T cells to recognize CENPM-overexpressing cancer cells

  • Therapeutic vaccines: Create peptide vaccines targeting CENPM epitopes presented on cancer cells

• Synthetic lethality approaches:

  • Identify genes that, when inhibited in combination with CENPM, cause selective cancer cell death

  • Screen for compounds that specifically kill cells with high CENPM expression

  • Target downstream effectors of CENPM that cancer cells become dependent upon

• Delivery systems for tumor-specific targeting:

  • Nanoparticle delivery of CENPM-targeting agents to enhance tumor accumulation

  • Antibody-drug conjugates targeting surface markers on CENPM-overexpressing tumors

  • Tumor-targeting peptides conjugated to CENPM inhibitors

The table below summarizes potential therapeutic approaches based on CENPM's functions:

These therapeutic strategies collectively represent promising avenues for translating CENPM research into novel cancer treatments, particularly for tumors showing CENPM overexpression.

What are the current limitations in CENPM antibody research and future research priorities?

Current limitations in CENPM antibody research span technical, biological, and translational domains, highlighting several priorities for future investigation:

• Technical limitations:

  • Limited availability of thoroughly validated CENPM antibodies targeting different epitopes

  • Inconsistent performance of antibodies across different applications and species

  • Challenges in detecting post-translational modifications of CENPM

  • Need for standardized protocols for CENPM detection across research laboratories

• Biological knowledge gaps:

  • Incomplete understanding of CENPM's precise molecular function beyond centromere assembly

  • Limited characterization of CENPM protein interactions in different cellular contexts

  • Unclear mechanisms by which CENPM influences metabolic reprogramming and immune infiltration

  • Insufficient data on CENPM expression in rare cancer types and subtypes

• Translational research limitations:

  • Lack of prospective clinical studies validating CENPM as a biomarker

  • Absence of specific CENPM inhibitors for therapeutic testing

  • Limited understanding of CENPM's role in treatment resistance mechanisms

  • Need for improved animal models to study CENPM function in vivo

• Future research priorities:

  • Development of highly specific monoclonal antibodies suitable for multiple applications

  • Comprehensive mapping of CENPM interactome in normal and cancer cells

  • Detailed characterization of CENPM's structural domains and their functions

  • Investigation of CENPM's role in cancer stem cell maintenance

  • Exploration of CENPM as a therapeutic target, particularly in combination with immunotherapy

  • Longitudinal studies tracking CENPM expression during cancer progression and treatment

  • Mechanistic studies on how CENPM influences glucose metabolism and the EMT process

• Methodological advancements needed:

  • Single-cell analysis of CENPM expression and function within heterogeneous tumors

  • Development of CENPM reporter systems for live-cell imaging

  • Creation of inducible CENPM knockout/knockin models for temporal studies

  • Systems biology approaches integrating multi-omics data related to CENPM function

Addressing these limitations through focused research efforts will advance our understanding of CENPM's role in cancer biology and potentially lead to new diagnostic and therapeutic approaches targeting this promising biomarker.

How can researchers integrate CENPM expression data with other biomarkers for improved cancer characterization?

Integrating CENPM expression data with other biomarkers represents a powerful approach for comprehensive cancer characterization, enabling more precise diagnosis, prognosis, and treatment selection:

• Multi-omics integration strategies:

  • Combine CENPM expression with genomic alterations (mutations, copy number variations) to identify correlations with specific genetic profiles

  • Integrate transcriptomic, proteomic, and metabolomic data to position CENPM within functional networks

  • Implement machine learning algorithms to discover patterns linking CENPM with other molecular features

  • Develop multi-parameter classification systems incorporating CENPM alongside established biomarkers

• Clinical data integration approaches:

  • Correlate CENPM expression with traditional clinicopathological parameters (tumor size, stage, grade)

  • Create integrated prognostic models combining CENPM with other molecular markers

  • Develop nomograms incorporating CENPM expression for individualized outcome prediction

  • Perform longitudinal analyses tracking CENPM and other biomarkers during treatment and disease progression

• Immune profile integration:

  • Combine CENPM expression with immune cell infiltration patterns for comprehensive immune profiling

  • Create multiplex immunohistochemistry panels including CENPM alongside immune checkpoint markers

  • Integrate CENPM with T-cell receptor repertoire data to assess correlation with immune diversity

  • Develop composite scores combining CENPM with established immunotherapy response predictors

• Metabolic signature integration:

  • Correlate CENPM expression with glycolytic enzyme levels to develop metabolic fingerprints

  • Integrate CENPM data with metabolite profiles from mass spectrometry

  • Create pathway activity scores combining CENPM with multiple metabolic markers

  • Analyze CENPM in conjunction with metabolic imaging features (e.g., FDG-PET signals)

• Practical implementation in research and clinical settings:

  • Establish standardized scoring systems quantifying CENPM alongside other biomarkers

  • Develop multiplexed detection methods (e.g., sequential IHC, mass cytometry) for simultaneous assessment

  • Create user-friendly bioinformatic tools for integrated biomarker analysis

  • Design clinical trials stratifying patients based on integrated biomarker profiles including CENPM

The table below demonstrates an example of how CENPM integration with other biomarkers could improve breast cancer subtyping: